WO2016029021A1 - Gamma-diketones for treatment and prevention of aging skin and wrinkles - Google Patents

Gamma-diketones for treatment and prevention of aging skin and wrinkles Download PDF

Info

Publication number
WO2016029021A1
WO2016029021A1 PCT/US2015/046120 US2015046120W WO2016029021A1 WO 2016029021 A1 WO2016029021 A1 WO 2016029021A1 US 2015046120 W US2015046120 W US 2015046120W WO 2016029021 A1 WO2016029021 A1 WO 2016029021A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
group
alkyl
unsubstituted
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/046120
Other languages
English (en)
French (fr)
Inventor
John Hood
Sunil Kumar Kc
Osman Kibar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosplice Therapeutics Inc
Original Assignee
Samumed LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201580056841.7A priority Critical patent/CN107106549B/zh
Priority to SI201530999T priority patent/SI3206686T1/sl
Priority to EP15833863.2A priority patent/EP3206686B1/en
Priority to KR1020177007464A priority patent/KR102165385B1/ko
Priority to MX2017002285A priority patent/MX368248B/es
Priority to ES15833863T priority patent/ES2762559T3/es
Priority to DK15833863.2T priority patent/DK3206686T3/da
Priority to SM20190709T priority patent/SMT201900709T1/it
Priority to RU2017108750A priority patent/RU2727039C2/ru
Priority to CA2958580A priority patent/CA2958580C/en
Priority to MA40454A priority patent/MA40454B1/fr
Priority to LTEP15833863.2T priority patent/LT3206686T/lt
Priority to JP2017529598A priority patent/JP6766047B2/ja
Priority to AU2015305373A priority patent/AU2015305373B2/en
Application filed by Samumed LLC filed Critical Samumed LLC
Priority to BR112017003959-1A priority patent/BR112017003959B1/pt
Priority to HRP20192161TT priority patent/HRP20192161T1/hr
Priority to RS20191605A priority patent/RS59797B1/sr
Priority to PL15833863T priority patent/PL3206686T3/pl
Publication of WO2016029021A1 publication Critical patent/WO2016029021A1/en
Priority to IL250663A priority patent/IL250663B/en
Anticipated expiration legal-status Critical
Priority to ZA2017/01460A priority patent/ZA201701460B/en
Priority to CY20191101314T priority patent/CY1122603T1/el
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • A61K8/70—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine containing perfluoro groups, e.g. perfluoroethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use

Definitions

  • the present disclosure relates to compounds, cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or wrinkles of skin, the methods comprising application of the disclosed compounds or compositions.
  • Mammalian epidermis and its appendages provide a barrier to keep harmful elements out of the body and essential body fluids in.
  • the epidermis must protect itself as well as the underlying tissues.
  • the epidermis is also exposed to mutagenic ultraviolet radiation.
  • nonhaired or sparsely haired regions such as most human skin, the epidermis is thicker than that of furred skin, and in these locations the skin functions primarily in a protective role.
  • the constant assaults on the epidermis necessitate self-renewal, making the epidermis a prime example of an adult tissue that undergoes continual and rapid flux.
  • Aged skin differs from youthful skin both in appearance and in function.
  • the aged epidermis lacks keratinocytes and is physically thinner, but mostly from effacement of the rete ridges.
  • aging slows wound healing, prolongs epidermal turnover, and impairs barrier formation.
  • the skin appears thin, wrinkled, bruised, and rough. Wrinkling and bruising can also result from aging-related changes in the dermis.
  • the dermis too, is characteristically thinner in aged persons.
  • Aged fibroblasts are less likely to synthesize normal amounts of collagen, elastin, laminin glycosaminoglycans, and fibronectin.
  • the dermis can, in such cases, lack elasticity, strength, vessel support, remodeling abilities, and ground substances. For example, rete ridges can be effaced, and basal cells can no longer display villous projections into the dermis.
  • Epidermal cell turnover is reduced up to 50% in the aged as compared to youth. For example, melanocyte numbers can decrease 8-20% per decade. There are fewer Langerhans cells in the aged, and those present are often functionally impaired.
  • Collagen synthesis decreases, for example, up to 30%> within 4 years of menopause in women. The numbers of collagen and elastic fibers are also decreased.
  • the dermis can also become less echogenic to ultrasounds, consistent with changes in collagen and elastic tissues.
  • the present disclosure relates to compounds, compositions comprising the same, and methods of using the compounds or compositions for treating, protecting, and/or altering (e.g., improving) the condition and/or aesthetic appearance of skin, including, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin and/or improving the aesthetic appearance of fine lines and/or wrinkles of skin, caused by, for example, cellular senescence, environmental damage or dermatoheliosis.
  • the disclosure also relates to methods for stimulating skin cell renewal, promoting fibroblast proliferation, and/or synthesizing elastin, collagen, proteoglycans, or new connective tissue, thereby reducing wrinkles, restoring elasticity, resiliency, and/or suppleness to the skin.
  • compositions described herein can be employed for cosmetic uses, dermopharmaceutical uses, or both cosmetic and dermopharmaceutical uses.
  • a "cosmetic”, as used herein, can be contacted with the skin, such as by being rubbed, poured, sprinkled, or sprayed on the skin or otherwise introduced into or onto the skin, and is intended to improve the aesthetic appearance of the skin, such as by cleansing, beautifying, promoting attractiveness, or altering, e.g., improving, the aesthetic appearance
  • a cosmetic benefit is typically visual or aesthetic, and can be evaluated using subjective or objective assays.
  • a "dermopharmaceutical” as used herein can similarly be contacted with the skin, and is intended to be used in the treatment, mitigation or prevention of a disease or disorder of the skin, and/or is intended to affect the structure or a function of the skin.
  • a dermopharmaceutical typically has a physiological, pharmacological, and/or therapeutic effect on the skin.
  • a dermopharmaceutical can result in an improved aesthetic appearance of the skin by virtue of its physiological, pharmacological, or therapeutic effects.
  • a dermopharmaceutical benefit can be evaluated using subjective or objective assays.
  • the present disclosure provides a cosmetic or dermopharmaceutical composition for improving the condition and/or aesthetic appearance of skin, wherein the composition comprises a compound according to Formula I, II, Ilia, Illb, and/or IV.
  • the present disclosure provides a cosmetic or dermopharmaceutical composition for altering the aesthetic appearance of skin associated with or affected by, or for preventing or reducing, wrinkles, dry skin, sensitive skin, or dermatological symptoms caused by ineffective homeostatic regulation of healthy skin, wherein the composition comprises a compound according to Formula I, II, Ilia, Illb, and/or IV.
  • the present disclosure provides a cosmetic or dermopharmaceutical composition for altering the aesthetic appearance of skin associated with or affected by wrinkling, sagging, and/or loss of skin elasticity, wherein the composition comprises a compound according to Formula I, II, Ilia, Illb, and/or IV.
  • the disclosure relates to the use of a compound according to Formula I, II, Ilia, Illb, and/or IV for altering the aesthetic appearance of skin associated with or affected by wrinkles and/or fine lines, wizened skin, a lack of elasticity and/or tonus of the skin, thinning of the dermis, degradation of collagen fibers, flaccid skin, thinned skin, and/or the internal degradation of the skin following exposure to ultraviolet radiation.
  • the present disclosure provides a cosmetic or dermopharmaceutical composition for altering the aesthetic appearance of skin associated with or affected by, or for treating or preventing, a skin condition/disorder accompanied by a loss of skin elasticity, wherein the composition comprises a compound according to Formula I, II, Ilia, Illb, and/or IV.
  • the present disclosure provides a cosmetic or dermopharmaceutical composition for altering the aesthetic appearance of skin associated with or affected by, or for treating or preventing, acne, wherein the composition comprises a compound according to Formula I, II, Ilia, Mb, and/or IV.
  • the present disclosure provides a cosmetic or dermopharmaceutical composition for treating or preventing deterioration in skin viscoelasticity, wherein the composition comprises a compound according to Formula I, II, Ilia, Illb, and/or IV.
  • the present disclosure provides a cosmetic or dermopharmaceutical composition for treating or preventing vitiligo (skin condition in which there is a loss of brown color (pigment) from areas of skin), wherein the composition comprises a compound according to Formula I, II, Ilia, Illb, and/or IV.
  • the disclosure provides methods for increasing cell or tissue regeneration. Such methods include administering to a vertebrate subject in need thereof a compound according to Formula I, II, Ilia, Illb, and/or IV, or a dermatologically acceptable salt thereof.
  • the present disclosure provides a cosmetic or dermopharmaceutical composition for activating or promoting proliferation and/or mobility of skin keratinocyte and/or dermis fibroblast, for example, to realize skin regeneration, wherein the composition comprises a compound according to Formula I, II, Ilia, Illb, and/or IV.
  • the present disclosure provides a cosmetic or dermopharmaceutical composition for increasing or improving epidermal cell repair activity, for example, in a human, wherein the composition comprises a compound according to Formula I, II, Ilia, Illb, and/or IV.
  • the present disclosure provides a cosmetic or dermopharmaceutical composition for increasing or improving the barrier function and/or viability of the skin, wherein the composition comprises a compound according to Formula I, II, Ilia, Illb, and/or IV.
  • the present disclosure provides a cosmetic or dermopharmaceutical composition for increasing fibroblast proliferation, keratinocyte proliferation, and/or expression of collagen, or reducing collagenase activity, wherein the composition comprises a compound according to Formula I, II, Ilia, Illb, and/or IV.
  • the disclosure relates to the use of a compound according to Formula I, II, Ilia, Illb, and/or IV as a medicament for treating or preventing a wound healing disorder in a mammal.
  • the disclosure relates to the use of a compound according to Formula I, II, Ilia, Illb, and/or IV as a medicament for treating or preventing a wound such as a bedsore in a mammal.
  • Some embodiments provided herein include cosmetic or dermopharmaceutical compositions comprising one or more of the compounds provided herein and a dermatologically acceptable carrier.
  • One embodiment provided herein includes compounds of Formula I:
  • Ring A is a 7-12 membered heteroaryl, with the proviso that a carbon atom on the ring is attached to the carbonyl carbon;
  • Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, with the proviso that a carbon atom on the ring is attached to the carbonyl carbon;
  • R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -C 1-3 haloalkyl, halide, - OR 3 , and CN;
  • R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH2OH, -CH 2 N(R 3b )2, -Ci-3 haloalkyl, halide, -OR 3 , and CN;
  • each R 3 is independently selected from the group consisting of H, unsubstituted - Ci-6 alkyl, and -C1-3 haloalkyl;
  • each R 3b is independently selected from the group consisting of H and unsubstituted -Ci-3 alkyl
  • each n is 0 to 10;
  • each m is 0 to 5.
  • Another embodiment provided herein includes compounds of Formula
  • Ring C is a 5-6 membered heteroaryl, with the proviso that a carbon atom on the ring is attached to the carbonyl carbon;
  • Ring D is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, with the proviso that a carbon atom on the ring is attached to the carbonyl carbon;
  • R 4 is a substituent attached to Ring C and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -C1-3 haloalkyl, halide, - OR 6 , and CN;
  • R 5 is a substituent attached to Ring D and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH2OH, -CH 2 N(R 6b ) 2 , -Ci-3 haloalkyl, halide, -OR 6 , and CN;
  • each R 6 is independently selected from the group consisting of H, unsubstituted - Ci-6 alkyl, and -C 1-3 haloalkyl;
  • each R 6b is independently selected from the group consisting of H and unsubstituted -Ci-3 alkyl
  • each q is 0 to 4.
  • each p is 0 to 5.
  • Another embodiment provided herein includes compounds of Formula
  • R 7 is a substituent attached to the phenyl ring and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH2OH, -CH2N(R 9a ) 2 , -Ci-3 haloalkyl, halide, -OR 9 , and CN;
  • R 8 is a substituent attached to the phenyl ring and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH2OH, -CH 2 N(R 9a ) 2 , -Ci-3 haloalkyl, halide, -OR 9 , and CN;
  • each R 9 is independently selected from the group consisting of H, unsubstituted - Ci-6 alkyl, and -C1-3 haloalkyl;
  • each R 9a is independently selected from the group consisting of H and unsubstituted -Ci-3 alkyl
  • each q is 1 to 5;
  • each p is 0 to 5.
  • Another embodiment provided herein includes compounds of Formula
  • R 10 is selected from the group consisting of H, unsubstituted -C 1-6 alkyl, -C 1-3 haloalkyl, halide, -OR 13 , and CN;
  • R 11 is selected from the group consisting of unsubstituted -Ci-6 alkyl, -CH2OH, - CH 2 N(R 13b ) 2 , -Ci-3 haloalkyl, halide, -OR 13 , and CN;
  • R 12 is a substituent attached to the phenyl ring and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH2OH, -CH 2 N(R 13b ) 2 , -Ci-3 haloalkyl, halide, -OR 13 , and CN;
  • each R 13 is independently selected from the group consisting of unsubstituted -C 1-6 alkyl, and -C1-3 haloalkyl;
  • each R 13b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl
  • each q is 0 to 5.
  • Another embodiment provided herein includes compounds of Formula
  • R 14 is selected from the group consisting of unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl;
  • R 15 is selected from the group consisting of unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl;
  • R is a substituent attached to the phenyl ring and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, CH 2 OH, -CH2N(R 17b ) 2 , -Ci-3 haloalkyl, halide, -OR 17 , and CN;
  • each R 17 is independently selected from the group consisting of unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl;
  • each R 17b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl
  • each q is 0 to 5.
  • Another embodiment provided herein includes compounds of Formula
  • Ring G is selected from the group consisting of , and a 5-6 membered heteroaryl(R ) z , with the proviso that a carbon atom on the heteroaryl ring is attached to the carbonyl carbon;
  • each R 18 is a substituent attached to Ring F and is independently selected at each occurrence from the group consisting of -C1-3 haloalkyl, halide, -OR 20 , and CN;
  • R 19a is a substituent attached to the para position of phenyl and is selected from the group consisting of H, unsubstituted -C2-6 alkyl, -CH2OH, -CH 2 N(R 21 ) 2 , -C1-3 haloalkyl, F, Br, I, -OR 20 , and CN;
  • R is a substituent attached to the meta or ortho position of phenyl and is selected from the group consisting of H, unsubstituted -C2-6 alkyl, -CH2OH, -CH 2 N(R 21 )2, -C1-3 haloalkyl, halide, -OR 20 , and CN;
  • R 19c is a substituent attached to the phenyl and is independently selected at each occurrence from the group consisting of -CH2OH, -CH 2 N(R 21 ) 2 , -C1-3 haloalkyl, halide, - OR 20 , and CN;
  • R 19d is a substituent attached to the heteroaryl ring and is independently selected at each occurrence from the group consisting of -CH2OH, -CH 2 N(R 21 ) 2 , -C1-3 haloalkyl, halide, -OR 20 , and CN;
  • each R 20 is independently selected from the group consisting of H, unsubstituted - C3-6 alkyl and -C1-3 haloalkyl;
  • each R 21 is independently selected from the group consisting of H and unsubstituted -Ci-3 alkyl
  • k 0 to 5;
  • p 0 to 13;
  • r 1 to 5;
  • z is 0 to 4.
  • Some embodiments include stereoisomers of a compound of Formula I, II, Ilia, Illb, and/or IV.
  • Some embodiments include prodrugs of a compound of Formula I, II, Ilia, Illb, and/or IV.
  • prodrugs of a compound of Formula I, II, Ilia, Mb, and/or IV can be prodrug polymer conjugates for delayed release or extended release.
  • compositions comprising a compound of Formula I, II, Ilia, Illb, and/or IV and a dermatologically acceptable carrier, diluent, or excipient.
  • FIG. 1 is a line graph showing the average change in roughness from baseline of test subjects skin after topical treatment of the periorbital areas by compound #222 (0.05% in oil, 0.05% in PEG, 0.15% in oil, and 0.15% in PEG). Roughness was determined by Visioscan. Each data point is the average of 20 or 21 test subjects.
  • FIG. 2 is a line graph showing the average percent wrinkle reduction from baseline of test subjects skin after topical treatment of the periorbital areas by compound #222 (0.05% in oil, 0.05% in PEG, 0.15% in oil, and 0.15% in PEG). Wrinkle reduction was determined by Visioscan. Each data point is the average of 20 or 21 test subjects.
  • ⁇ -diketones useful for treating, protecting, and improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating, and/or improving the appearance of fine lines and/or wrinkles of skin.
  • application of the ⁇ -diketones provided herein can increase collagen replacement and retention, and can also, in some embodiments, increase cellular proliferation of the epidermis and dermis.
  • Cosmetic or dermopharmaceutical compositions comprising one or more compounds according to Formula I, la, lb, Ic, Id, Ie, If, Ig, Ih, Ii, II, Ila, lib, lie, Hd, He, Hf, III, Ilia, IHb, Hie, Hid, and/or IV, or a dermatologically acceptable salt thereof, and a dermatologically acceptable carrier are also provided herein.
  • Ring A is a 7-12 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon.
  • Ring A is a 7-12 membered heteroaryl, wherein a carbon atom on the benzene ring is attached to the carbonyl carbon.
  • Ring A is a 7-12 membered heteroaryl, wherein a carbon atom on the heteroaromatic ring is attached to the carbonyl carbon.
  • Ring A is a 7-12 membered heteroaryl, wherein a carbon atom on the heterocyclic aliphatic ring is attached to the carbonyl carbon.
  • Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, with the proviso that a carbon atom on the ring is attached to the carbonyl carbon.
  • R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 3 is independently selected from the group consisting of H, unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl.
  • each R 3b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl.
  • n is 0 to 10. In some embodiments of Formula I, n is 1 to 10.
  • m is 0 to 5.
  • m is 1 to 5.
  • Ring A is a 9-membered bicyclic heteroaryl ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S.
  • Ring A is a 10-membered bicyclic heteroaryl ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S.
  • Ring A is selected from the group consisting of:
  • carbonyl carbon of Formula I can form a bond with any unsubstituted carbon on Ring A.
  • Ring A is selected from the group consisting of: ⁇ ⁇ " ⁇ , NH" ⁇ , ⁇ " ⁇ ? ⁇ " ⁇ ? b- ⁇ ? s- ⁇ , and ⁇ —* ⁇ ; wherein the carbonyl carbon of Formula I can form a bond with any unsubstituted carbon on Ring A.
  • Ring A is selected from the group consisting of: ⁇ wherein the carbonyl carbon of Formula I can form a bond with any unsubstituted carbon on the Ring A.
  • Ring A is selected from the group consisting of:
  • Ring A is selected from the group
  • Ring A is selected from the group consisting of
  • Ring A is selected from the group consisting of C o ⁇ ⁇ O ⁇ , NH ⁇ O* ⁇ ? and C o ⁇ O ⁇ ; wherein the carbonyl carbon of Formula I can form a bond with any unsubstituted carbon on the Ring A.
  • Ring A is selected from the group
  • Ring A is selected from the group consisting of
  • Some embodiments of Formula I include compounds of Formula (la): la
  • Ring A is ⁇ °
  • Ring B is selected from the group
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of unsubstituted -Ci-6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • R 2a is a substituent attached to the para position of phenyl and selected from the group consisting of unsubstituted -C 1-6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C 1-3 haloalkyl, CI, Br, I, -OR 3a , and CN.
  • R 2b is one substituent attached to the meta or ortho position of phenyl and selected from the group consisting of unsubstituted -Ci-6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3a , and CN.
  • R 2c is a substituent attached to the phenyl and are independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN; m is 2 to 5.
  • R 2d is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN; s is 1 to 4.
  • R 2e is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN; t is 1 to 4.
  • R 2e is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN; t is 0 to 4.
  • R 2f is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN; u is 1 to 3.
  • R 2g is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN; v is 1 to 3.
  • R 2g is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN; v is 0 to 3.
  • each R 3 is independently selected from the group consisting of H, unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl.
  • each R 3a is independently selected from the group consisting of unsubstituted -C 2-6 alkyl and -C1-3 haloalkyl.
  • each R 3b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl.
  • each W is independently N or C.
  • At least two W must be N.
  • each U is independently N or C.
  • At least one U must be N and at least one U must be C.
  • G is NH or O.
  • each J is independently N or C.
  • At least one J must be C.
  • n is 0 to 7.
  • n 1 to 7.
  • Ring A is selected from the group
  • Ring B is selected from the group
  • Ring B is selected from the group
  • Ring B is selected from the group
  • Ring B is selected from the group
  • Ring B is selected from the group
  • Ring B is selected from the group
  • At least one R 2e is a halide.
  • At least one R 2e is F.
  • At least one R 2e is CI.
  • At least one R 2e is Me.
  • At least one R 2e is OH.
  • at least one R is OMe.
  • At least one R 2e is CF 3 .
  • At least one R 2e is CN.
  • t is 1 and R 2e is F.
  • t is 2 and both R 2e are F.
  • t is 1 and R 2e is Me.
  • t is 2 and both R 2e are Me.
  • t is 1 and R 2e is CF 3 .
  • t is 2 and both R 2e are CF 3 .
  • t is 1 and R 2e is OMe.
  • t is 2 and both R 2e are OMe.
  • t is 2 and one R 2e is F and the other R 2e is Me.
  • t is 2 and one R 2e is F and the other R 2e is CF 3 .
  • t is 2 and one R 2e is F and the other R 2e is OMe.
  • t is 1 and R 2e is CN.
  • t is 2 and both R 2e are CN.
  • t is 2 and one R 2e is F and the other R 2e is CN.
  • At least one R 2e is -C 1-2 alkyl.
  • At least one R 2e is -C 1-3 alkyl.
  • At least one R 2e is -C 1-4 alkyl.
  • At least one R 2e is -C 1-5 alkyl.
  • At least one R 2e is -C 1-6 alkyl.
  • At least one R 2e is -C 2-6 alkyl.
  • At least one R 2e is -C 3-6 alkyl.
  • At least one R 2e is -C 4-6 alkyl.
  • At least one R 2e is -C 2-5 alkyl.
  • At least one R 2e is -C 3-4 alkyl.
  • n some embodiments of Formula ] a at least one R is halide.
  • At least one R 2f is F.
  • At least one R 2f is CI.
  • At least one R 2f is Me.
  • At least one R 2f is OH.
  • At least one R 2f is OMe.
  • At least one R 2f is CF 3 .
  • At least one R 2f is CN.
  • n some embodiments of Formula ] a, u is 1 and R 2f is F.
  • u is 2 and both R 2f are F.
  • n some embodiments of Formula ] a, u is 1 and R 2f is Me.
  • u is 2 and both R 2f are Me.
  • u is 1 and R 2f is CF 3 .
  • u is 2 and both R 2f are CF 3 .
  • u is 1 and R 2f is OMe.
  • u is 2 and both R 2f are OMe.
  • u is 2 and one R 2f is F and the other R 2f is Me.
  • u is 2 and one R is F and the other R 2f is CF 3 .
  • u is 2 and one R is F and the other R 2f is OMe
  • u is 1 and R 2f is CN.
  • u is 2 and both R 2f are CN.
  • u is 2 and one R 2f is F and the other R 2f is CN.
  • At least one R is -C 1-2 alkyl.
  • At least one R 2f is -C 1-3 alkyl.
  • At least one R 2f is -C 1-4 alkyl.
  • At least one R 2f is -C 1-5 alkyl.
  • At least one R 2f is -C 1-6 alkyl.
  • at least one R is -C2-6 alkyl.
  • At least one R 2f is -C3-6 alkyl.
  • At least one R 2f is -C4-6 alkyl.
  • At least one R 2f is -C2-5 alkyl.
  • At least one R 2f is -C3-4 alkyl.
  • v is 0.
  • v is 1.
  • v is 2.
  • At least one R 2g is halide.
  • At least one R 2g IS r is a member of Formula la.
  • At least one R 2g is CI.
  • At least one R 2g is Me.
  • At least one R 2g is OH.
  • At least one R 2g is OMe.
  • At least one R 2g is CF3.
  • At least one R 2g is CN.
  • v is 1 and R 2g is F.
  • v is 2 and both R 2g are F.
  • v is 1 and R 2g is Me.
  • v is 2 and both R 2g are Me.
  • v is 1 and R 2g is CF3.
  • v is 2 and both R 2g are CF3.
  • v is 1 and R 2g is OMe.
  • v is 2 and both R 2g are OMe.
  • v is 2 and one R 2g is F and the other R 2g is Me.
  • v is 2 and one R 2g is F and the other R 2g is CF 3 .
  • v is 2 and one R 2g is F and the other R 2g is OMe.
  • v is 1 and R 2g is CN.
  • v is 2 and both R 2 g are CN.
  • v is 2 and one R 2g is F and the other R 2g is CN.
  • At least one R 2g is -Ci-2 alkyl.
  • At least one R 2g is -Ci-3 alkyl.
  • At least one R 2g is -Ci-4 alkyl.
  • At least one R 2g is -Ci-5 alkyl.
  • At least one R 2g is -Ci-6 alkyl.
  • At least one R 2g is -C2-6 alkyl.
  • At least one R 2g is -C3-6 alkyl.
  • At least one R 2g is -C4-6 alkyl.
  • At least one R 2g is -C2-5 alkyl.
  • At least one R 2g is -C3-4 alkyl.
  • Some embodiments of Formula I include compounds of Formula (lb):
  • Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -C 1-6 alkyl, -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of unsubstituted -Ci-6 alkyl, -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 3 is independently selected from the group consisting of H, unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl.
  • each R 3b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl.
  • each M is independently selected from the group consisting of N, C, S and O.
  • both M are not O.
  • both M are not C.
  • m is 0 to 5.
  • m is 1 to 5.
  • n is 0 to 10.
  • n is 1 to 10.
  • Ring A is selected from the group
  • Some embodiments of Formula I include compounds of Formula (Ic):
  • Ring A In some embodiments of Formula Ic, Ring A
  • Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 3 is independently selected from the group consisting of H, unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl.
  • each R 3b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl.
  • each M is independently selected from the group consisting of N, C, S and O.
  • m is 0 to 5.
  • m is 1 to 5.
  • n is 0 to 10.
  • n 1 to 10.
  • Ring A is selected from the group consisting of
  • Some embodiments of Formula I include compounds of Formula (Id):
  • Ring A is .
  • Ring B is selected from the group
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • R 2a is one substituent attached to the para position of phenyl and is selected from the group consisting of H, unsubstituted - Ci-6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, CI, Br, I, -OR 3a , and CN.
  • R 2b is one substituent attached to the meta position of phenyl and is selected from the group consisting of H, unsubstituted - C2-6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, F, I, -OR 3 , and CN.
  • R 2c is one substituent attached to the ortho position of phenyl and is selected from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, F, Br, I, -OR 3 , and CN.
  • R is a substituent attached to the phenyl and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN; w is 1 to 5.
  • R 2ee is a substituent attached to the heteroaryl ring and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, - OR 3 , and CN; y is 0 to 3.
  • R 2c is a F.
  • R 2c is a Me.
  • R 2c is a OH.
  • R 2c is a OMe.
  • R 2c is a CF 3 .
  • R 2c is a CN.
  • R 2c is a -C 1-2 alkyl.
  • R 2c is a -Ci-3 alkyl.
  • R 2c is a -Ci_ 4 alkyl.
  • R 2c is a -Ci-5 alkyl.
  • R 2c is a -Ci-e alkyl.
  • R 2c is a -C 2 _ 6 alkyl
  • R 2c is a -C _ 6 alkyl
  • R 2c is a -C 4 -6 alkyl
  • R 2c is a -C2-5 alkyl
  • R 2c is a -C _ 4 alkyl
  • At least one R 2dd is F.
  • At least one R 2dd is CI.
  • At least one R 2dd is Me.
  • At least one R 2dd is OH.
  • At least one R 2dd is OMe.
  • At least one R 2dd is CF 3 .
  • At least one R 2dd is CN.
  • w is 2 to 5.
  • w is 1.
  • w is 2.
  • w is 1 and R 2dd is F.
  • w is 2 and both R 2dd are F.
  • w is 1 and R 2dd is Me.
  • w is 2 and both R 2dd are Me.
  • w is 1 and R 2dd is CF 3 .
  • w is 2 and both R 2dd are CF 3 .
  • w is 1 and R 2dd is OMe.
  • w is 2 and both R 2dd are OMe.
  • w is 2 and one R 2dd is F and the other R 2dd is Me.
  • w is 2 and one R 2dd is F and the other R 2dd is CF 3 .
  • w is 2 and one R 2dd is F and the other R 2dd is OMe.
  • w is 1 and R 2dd is CN.
  • w is 2 and both R 2dd are CN.
  • w is 2 and one R 2dd is F and the other R 2dd is CN.
  • At least one R 2dd is -C 1-2 alkyl.
  • At least one R 2dd is -C 1-3 alkyl.
  • At least one R 2dd is -C 1-4 alkyl.
  • At least one R 2dd is -C 1-5 alkyl.
  • At least one R 2dd is -C 1-6 alkyl.
  • At least one R 2dd is -C 2-6 alkyl.
  • At least one R 2dd is -C 3-6 alkyl.
  • At least one R 2dd is -C 4-6 alkyl.
  • At least one R 2dd is -C 2-5 alkyl.
  • At least one R 2dd is -C 3-4 alkyl.
  • y is 1.
  • y is 2.
  • At least one R 2ee is halide.
  • At least one R 2ee is F.
  • At least one R 2ee is CI.
  • At least one R 2ee is Me.
  • At least one R 2ee is OH.
  • At least one R 2ee is OMe.
  • At least one R 2ee is CF 3 .
  • At least one R 2ee is CN.
  • y is 1 and R 2ee is F.
  • y is 2 and both R 2ee are F.
  • y is 1 and R 2ee is Me.
  • y is 2 and both R 2ee are Me.
  • y is 1 and R 2ee is CF 3 .
  • y is 2 and both R 2ee are CF 3 .
  • y is 1 and R 2ee is OMe.
  • y is 2 and both R 2ee are OMe.
  • y is 2 and one R 2ee is F and the other R 2ee is Me.
  • y is 2 and one R 2ee is F and the other R 2ee is CF 3 .
  • y is 2 and one R 2ee is F and the other R 2ee is OMe.
  • y is 1 and R 2ee is CN.
  • y is 2 and both R 2ee are CN.
  • y is 2 and one R 2ee is F and the other R 2ee is CN.
  • At least one R 2ee is -C 1-2 alkyl. [00323] In some embodiments of Formula Id, at least one R 2ee is -C 1-3 alkyl.
  • At least one R 2ee is -Ci-4 alkyl.
  • At least one R 2ee is -Ci-5 alkyl.
  • At least one R 2ee is -Ci-6 alkyl.
  • At least one R 2ee is -C2-6 alkyl.
  • At least one R 2ee is -C3-6 alkyl.
  • At least one R 2ee is -C4-6 alkyl.
  • At least one R 2ee is -C2-5 alkyl. [00331] In some embodiments of Formula Id, at least one R 2ee is -C3-4 alkyl.
  • each R 3 is independently selected from the group consisting of H, unsubstituted -Ci-6 alkyl and -C1-3 haloalkyl.
  • each R 3a is independently selected from the group consisting of H, unsubstituted -C2-6 alkyl and -C1-3 haloalkyl.
  • each R 3b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl.
  • Q is S or NH.
  • n is 0 to 5.
  • n 1 to 5.
  • Ring A is selected from the group
  • R is H.
  • R 2b is H.
  • w 0.
  • Some embodiments of Formula I include compounds of Formula (Ie):
  • Ring A is
  • Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 3 is independently selected from the group consisting of H, unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl.
  • each R 3b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl.
  • each W is independently N or C
  • At least one W must be N.
  • Q is S or NH.
  • m is 0 to 5.
  • m is 1 to 5.
  • n is 0 to 4.
  • n 1 to 4.
  • Ring A is selected from the group
  • Some embodiments of Formula I include compounds of Formula (If):
  • Ring A is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -C 1-6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 3 is independently selected from the group consisting of H, unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl.
  • each R is independently selected from the group consisting of H and unsubstituted -C 1-3 alkyl.
  • each W is independently N or C.
  • m is 0 to 5.
  • m is 1 to 5.
  • n is 0 to 5.
  • n 1 to 5.
  • Ring A is selected from the group consisting of
  • Some embodiments of Formula I include compounds of Formula (Ig):
  • Ring A is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ring B is selected from the group
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -C 1-6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • R is one substituent attached to the para position of phenyl and is selected from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, F, I, -OR 3 , and CN.
  • R 2b is one substituent attached to the meta or ortho position of phenyl and is selected from the group consisting of unsubstituted -C2-6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • R 2c is a substituent attached to the phenyl and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN; m is 2-5.
  • R 2d is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN; s is 1-3.
  • R 2d is a substituent attached to the heteroaryl ring and are independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN; s is 0-4.
  • each R 3 is independently selected from the group consisting of H, unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl.
  • each R 3b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl.
  • Q is selected from the group consisting of O, S, and NH.
  • n is 0 to 5.
  • n 1 to 5.
  • Ring A is selected from the group
  • R is a F.
  • R is a OH.
  • R 2a is a OMe.
  • At least one R 2d is -CH2OH.
  • At least one R 2d is -CH2N(R 3b )2.
  • At least one R 2d is -CH2NH2.
  • At least one R 2d is -CFbNHMe.
  • At least one R 2d is -CH 2 NMe 2 .
  • At least one R 2d is -CFbNHEt.
  • At least one R 2d is -CH2N(Me)(Et).
  • At least one R 2d is -CH2NEt2.
  • Some embodiments of Formula I include compounds of Formula (Ih):
  • Ring A is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci-6 alkyl, -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of unsubstituted -Ci-6 alkyl, -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 3 is independently selected from the group consisting of H, unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl.
  • each R 3b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl.
  • each W is independently N or C.
  • At least one W must be N.
  • Q is selected from the group consisting of O, S, and NH.
  • m is 0 to 5.
  • m is 1 to 5.
  • n is 0 to 4.
  • n 1 to 4.
  • Ring A is selected from the group
  • Some embodiments of Formula I include compounds of Formula (Ii):
  • Ring B is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 1 is a substituent attached to Ring A and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 2 is a substituent attached to Ring B and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH 2 OH, -CH 2 N(R 3b ) 2 , -C1-3 haloalkyl, halide, -OR 3 , and CN.
  • each R 3 is independently selected from the group consisting of H, unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl.
  • each R 3b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl.
  • each W is independently N or C.
  • At least one W is C
  • Q is selected from the group consisting of O, S, and N.
  • m is 0 to 5.
  • m is 1 to 5.
  • n is 0 to 7.
  • n 1 to 7.
  • Ring A is selected from the group
  • R 1 is selected from the group consisting of F, CI, Me, OMe, OH, CF 3 , and CN.
  • R 1 is F; and n is 1.
  • each R 1 is the same.
  • R 1 is independently selected at each occurrence from the group consisting of F, CI, Me, OMe, OH, CF 3 , and CN; and n is 1 or 2.
  • Ring B is phenyl.
  • Ring B is a 5-membered heteroaryl containing 1-3 heteroatoms selected from the group consisting of N, O, and S.
  • Ring B is a 6-membered heteroaryl containing 1-2 nitrogen atoms.
  • At least one R 2d , R 2e , R 2f , or R 2g is -CH2OH.
  • At least one R 2a , R 2b , or R 2c is -CH2OH.
  • At least one R 2dd or R 2ee is - CH2OH.
  • At least one R 2d , R 2e , R 2f , or R 2g is -CH 2 N(R 3b ) 2 .
  • At least one R 2a , R 2b , or R 2c is -CH 2 N(R 3b ) 2 .
  • At least one R 2dd or R 2ee is - CH 2 N(R 3b ) 2 .
  • At least one R 2 is -CH 2 N(R 3b ) 2 .
  • At least one R 2d , R 2e , R 2f , or R 2g is -CH2NH2.
  • at least one R 2a , R 2b , or R 2c is -CH2NH2.
  • At least one R 2dd or R 2ee is - CH2NH2.
  • At least one R 2d , R 2e , R 2f , or R 2g is -CH 2 NHMe.
  • At least one R 2a , R 2b , or R 2c is -CH 2 NHMe.
  • At least one R 2dd or R 2ee is - CH 2 NHMe.
  • At least one R 2d , R 2e , R 2f , or R 2g is -CH 2 NMe 2 .
  • At least one R 2a , R 2b , or R 2c is -CH 2 NMe 2 .
  • At least one R 2dd or R 2ee is - CH 2 NMe 2 .
  • At least one R 2d , R 2e , R 2f , or R 2g is -CH 2 NHEt.
  • At least one R 2a , R 2b , or R 2c is -CH 2 NHEt.
  • At least one R 2dd or R 2ee is - CH 2 NHEt.
  • At least one R 2 is -CH 2 NHEt.
  • at least one R 2d , R 2e , R 2f , or R 2g is -CH 2 N(Me)(Et).
  • At least one R 2a , R 2b , or R 2c is -CH 2 N(Me)(Et).
  • At least one R 2dd or R 2ee is - CH 2 N(Me)(Et).
  • At least one R 2 is -CH 2 N(Me)(Et).
  • At least one R 2d , R 2e , R 2f , or R 2g is -CH 2 NEt 2 .
  • At least one R 2a , R 2b , or R 2c is -CH 2 NEt 2 .
  • At least one R 2dd or R 2ee is - CH 2 NEt 2 .
  • At least one R 2 is -CH 2 NEt 2 .
  • At least one R 2 is independently selected at each occurrence from the group consisting of F, CI, Me, OMe, OH, CF 3 , and CN.
  • R 2 is F.
  • At least one R 2 is CF 3 .
  • At least one R 2 is CN.
  • At least one R 2 is -Ci-2 alkyl.
  • At least one R 2 is -Ci-3 alkyl.
  • At least one R 2 is -Ci-4 alkyl.
  • At least one R 2 is -Ci-5 alkyl.
  • At least one R 2 is -Ci-6 alkyl.
  • At least one R 2 is -C2-6 alkyl.
  • At least one R 2 is -C3-6 alkyl.
  • At least one R 2 is -C4-6 alkyl.
  • Ring B is a phenyl or 6-membered heteroaryl; R 2 is selected from the group consisting of F, CI, Me, OMe, OH, CF3, and CN; m is 1; and R 2 is attached to an ortho carbon of the 6-membered ring.
  • Ring B is a phenyl; R 2 is selected from the group consisting of F, CI, Me, OMe, OH, CF3; and CN; m is 1; and R 2 is attached to an ortho position of the phenyl ring.
  • Ring B is a pyridine; R 2 is selected from the group consisting of F, CI, Me, OMe, OH, CF3, and CN; m is 1; and R 2 is attached to an ortho carbon of the pyridine ring.
  • R 2a is a CI.
  • R 2a is a Me.
  • R 2a is a CF 3 .
  • R 2a is a CN.
  • R 2a is a Me.
  • R 2a is a CF 3 .
  • R 2a is a CN.
  • R 2a is a -C 1-2 alkyl.
  • R 2a is a -C 1-3 alkyl.
  • R 2a is a -C 1-4 alkyl.
  • R 2a is a -C 1-5 alkyl.
  • R 2a is a -C 1-6 alkyl.
  • R 2a is a -C 2-6 alkyl.
  • R 2a is a -C 3-6 alkyl.
  • R 2a is a -C 4-6 alkyl.
  • R 2a is a -C 2-5 alkyl.
  • R 2a is a -C 3-4 alkyl.
  • R 2b is a halide
  • R 2b is a F.
  • R 2b is a CI.
  • R 2b is a Me.
  • R 2b is a OH.
  • R 2b is a OMe.
  • R 2b is a CF 3 .
  • R 2b is a CN.
  • R 2b is a -C 1-2 alkyl.
  • R 2b is a -C 1-3 alkyl.
  • R 2b is a -C 1-4 alkyl.
  • R 2b is a -C 1-5 alkyl.
  • R 2b is a -C 1-6 alkyl.
  • R 2b is a -C 3 _6 alkyl.
  • R 2b is a -C2-5 alkyl.
  • At least one R 2c is halide.
  • At least one R 2c is F.
  • At least one R 2c is CI.
  • At least one R 2c is Me.
  • At least one R 2c is OH.
  • At least one R 2c is OMe.
  • At least one R 2c is CF 3 .
  • At least one R 2c is CN.
  • R 2c is a F.
  • R 2c is CF 3 and m is 1.
  • R 2c is CF 3 and m is 2.
  • R 2c is OMe and m is 1.
  • R 2c is OMe and m is 2.
  • m is 2 and one R 2c is F and the other R 2c is CF 3 .
  • R 2c is CN and m is 1.
  • R 2c is CN and m is 2.
  • m is 2 and one R 2c is F and the other R 2c is CN.
  • At least one R 2c is -C 1-2 alkyl.
  • At least one R 2c is -C 1-3 alkyl.
  • At least one R 2c is -C 1-4 alkyl.
  • At least one R 2c is -C 1-5 alkyl.
  • At least one R 2c is -C 1-6 alkyl.
  • At least one R 2c is -C2-6 alkyl.
  • At least one R 2c is -C3-6 alkyl.
  • At least one R 2c is -C4-6 alkyl.
  • At least one R 2c is -C2-5 alkyl.
  • At least one R 2c is -C3-4 alkyl.
  • At least one R 2d is halide.
  • At least one R 2d is F.
  • At least one R 2d is CI.
  • At least one R 2d is Me.
  • At least one R 2d is OH.
  • At least one R 2d is OMe.
  • At least one R 2d is CF3.
  • at least one R is CN.
  • s is 2 and both R 2d are F.
  • s is 1 and R 2d is CF 3 .
  • s is 2 and both R 2d are CF 3 .
  • s is 1 and R 2d is OMe.
  • s is 2 and one R is F and the other R 2d is Me.
  • s is 2 and one R 2d is F and the other R 2d is CF 3 .
  • s is 2 and one R 2d is F and the other R 2d is OMe.
  • s is 1 and R 2d is CN.
  • s is 2 and both R 2d are CN.
  • s is 2 and one R 2d is F and the other R 2d is CN.
  • At least one R is -C 1-2 alkyl.
  • At least one R 2d is -C 1-3 alkyl.
  • At least one R 2d is -C 1-4 alkyl.
  • At least one R 2d is -C 1-5 alkyl.
  • At least one R 2d is -C 1-6 alkyl.
  • at least one R is -C 2-6 alkyl.
  • At least one R 2d is -C3-6 alkyl.
  • At least one R 2d is -C4-6 alkyl.
  • At least one R 2d is -C2-5 alkyl.
  • At least one R 2d is -C3-4 alkyl.
  • Some embodiments of the present disclosure include compounds of Formula (II):
  • Ring C is a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon.
  • Ring D is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon.
  • each R 4 is a substituent attached to Ring C and is independently selected at each occurrence from the group consisting of H, unsubstituted -C 1-6 alkyl, -C1-3 haloalkyl, halide, -OR 6 , and CN.
  • each R 4 is a substituent attached to Ring C and is independently selected at each occurrence from the group consisting of unsubstituted -Ci-6 alkyl, -C1-3 haloalkyl, halide, -OR 6 , and CN.
  • each R 5 is a substituent attached to Ring D and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, halide, -OR 6 , and CN.
  • each R 5 is a substituent attached to Ring D and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, halide, -OR 6 , and CN.
  • each R 6 is independently selected from the group consisting of H, unsubstituted -Ci-6 alkyl and -C1-3 haloalkyl.
  • each R 6b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl.
  • each q is 0 to 4.
  • each q is 1 to 4.
  • each p is 0 to 5.
  • each p is 1 to 5.
  • Ring C is a 5-membered heteroaryl ring containing 1-3 heteroatoms selected from the group consisting of N, O, and S.
  • Ring C is a 6-membered heteroaryl ring containing 1-2 nitrogens.
  • 3 ⁇ 4 is selected from the
  • each R 4 is independently selected from the group consisting of F, CI, Me, OMe, OH, CF 3 , and CN.
  • Ring C is selected from the group consisting of:
  • Ring D is a phenyl or 6-membered heteroaryl
  • R 5 is selected from the group consisting of F, CI, Me, OMe, OH, CF 3 and CN
  • q is 1
  • R 5 is attached to an ortho carbon of the 6-membered ring.
  • Ring D is a phenyl
  • R 5 is selected from the group consisting of F, CI, Me, OMe, OH, CF 3 and CN; q is 1; and R 5 is attached to an ortho position of the phenyl ring.
  • Ring D is a pyridine
  • R 5 is selected from the group consisting of F, CI, Me, OMe, OH, CF 3 and CN; q is 1; and R 5 is attached to an ortho carbon of the pyridine ring.
  • Some embodiments of Formula II include compounds of Formula (Ha):
  • Ring C is
  • Ring D is selected from the group
  • each R 4 is a substituent attached to Ring C and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 6 , and CN.
  • each R 4 is a substituent attached to Ring C and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 6 , and CN.
  • R 5a is a substituent attached to the ring and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, halide, -OR 6a , and CN; j is 1 to 5.
  • R 5b is a substituent attached to the ring and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, F, I, -OR 6a , and CN; k is 1 to 4.
  • R 5c is a substituent attached to the ring and is independently selected at each occurrence from the group consisting of H,
  • R 5c is a substituent attached to the ring and is independently selected at each occurrence from the group consisting of unsubstituted -Ci-e alkyl, -CH 2 OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, halide, -OR 6 , and CN; x is 0 to 3.
  • x is 0.
  • R 5d is a substituent attached to the ring and are independently selected at each occurrence from the group consisting of unsubstituted -Ci-e alkyl, -CH 2 OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, halide, -OR 6 , and CN; z is 1 or 2.
  • R 5e is a substituent attached to the ring and are independently selected at each occurrence from the group consisting of H, unsubstituted -Ci-e alkyl, -CH 2 OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, halide, -OR 6 , and CN; s is 1 to 3.
  • R 5e is a substituent attached to the ring and are independently selected at each occurrence from the group consisting of unsubstituted -Ci-e alkyl, -CH 2 OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, halide, -OR 6 , and CN; s is 0 to 3.
  • each R 6 is independently selected from the group consisting of H, unsubstituted -C 1-6 alkyl and -C1-3 haloalkyl.
  • each R 6a is independently selected from the group consisting of H, unsubstituted -C 2-6 alkyl and -C1-3 haloalkyl.
  • each R 6b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl.
  • each A is independently N or C.
  • At least two A must be N.
  • each J is independently N or C.
  • At least one J must be N and at least one J must be C.
  • each U is independently N or C.
  • At least one U must be C.
  • Q is O or N.
  • p is 0 to 4.
  • p is 1 to 4.
  • Ring D is selected from the group
  • Ring D is selected from the consisting of:
  • Some embodiments of Formula II include compounds of Formula (lib)
  • Ring C is A
  • Ring D is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, wherein a carbon atom on the ring is attached to the carbonyl carbon.
  • each R 4 is a substituent attached to Ring C and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 6a , and CN.
  • each R 4 is a substituent attached to Ring C and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_6 alkyl, -C 1-3 haloalkyl, halide, -OR 6a , and CN.
  • each R 5 is a substituent attached to Ring D and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 6b ) 2 , -C 1-3 haloalkyl, halide, -OR 6 , and CN.
  • each R 5 is a substituent attached to Ring D and is independently selected at each occurrence from the group consisting of unsubstituted -C 1-6 alkyl, -CH 2 OH, -CH 2 N(R 6b ) 2 , -C 1-3 haloalkyl, halide, -OR 6 , and CN.
  • each R 6 is independently selected from the group consisting of H, unsubstituted -C 1-6 alkyl, and -C 1-3 haloalkyl.
  • each R 6a is independently selected from the group consisting of unsubstituted -C 1-6 alkyl and -C 1-3 haloalkyl.
  • each R 6b is independently selected from the group consisting of H and unsubstituted -C 1-3 alkyl.
  • each A is independently N or C.
  • At least two A must be N.
  • p is 0 to 3.
  • p is 1 to 3.
  • q is 1 to 5.
  • q is 0 to 5.
  • Ring C is selected from the group
  • Ring D is phenyl.
  • ⁇ is selected f 7 ⁇ F) protest+ 7 (F 3 C),
  • Ring D is a 5-membered heteroaryl containing 1 -3 heteroatoms selected from the group consisting of N, O, and S.
  • Ring D is a 6-membered heteroaryl containing 1-2 nitrogen atoms.
  • At least one R 5 is -CH 2 OH.
  • at least one R 5 is - CH 2 N(R 3b ) 2 .
  • At least one R 5 is - CH2NH2.
  • At least one R 5 is - CH 2 NHMe.
  • At least one R 5 is - CH 2 NMe 2 .
  • At least one R 5 is - CH 2 NHEt.
  • At least one R 5 is - CH 2 N(Me)(Et).
  • At least one R 5 is - CH 2 NEt 2 .
  • each R 5 is independently selected from the group consisting of F, CI, Me, OMe, OH, CF3, and CN.
  • R 5 is a halide
  • R 5 is F.
  • R 5 is CI.
  • R 5 is Me.
  • R 5 is OH.
  • R 5 is OMe.
  • R 5 is CF3.
  • R 5 is CN
  • R 5 is F; and q is 1.
  • R 5 is F; and q is 2.
  • R 5 is Me; and q is 1.
  • R 5 is Me; and q is 2.
  • R 5 is CF 3 ; and q is 1.
  • R 5 is CF 3 ; and q is 2.
  • R 5 is OMe; and q is 1.
  • R 5 is OMe; and q is 2.
  • R 5 is F and Me; and q is
  • R 5 is F and CF 3 ; and q is
  • R 5 is F and OMe; and q is
  • R 5 is CN; and q is 1.
  • R 5 is CN; and q is 2.
  • R 5 is F and CN; and q is
  • At least one R is -G_ 2 alkyl.
  • At least one R 5 is -G_ alkyl.
  • At least one R 5 is -C 1-4 alkyl.
  • At least one R 5 is -C 1-5 alkyl.
  • At least one R 5 is -C 1-6 alkyl.
  • At least one R 5 is -C 2-6 alkyl.
  • At least one R 5 is -C 3-6 alkyl.
  • At least one R 5 is -C 4-6 alkyl.
  • At least one R 5 is -C 2-5 alkyl.
  • At least one R 5 is -C3-5 alkyl.
  • Some embodiments of Formula II include compounds of Formula (He): lie
  • Ring C is
  • Ring D is selected from the group
  • each R 4 is a substituent attached to Ring C and is independently selected at each occurrence from the group consisting of H, unsubstituted -C 1-6 alkyl, -C1-3 haloalkyl, halide, -OR 6 , and CN.
  • each R 4 is a substituent attached to Ring C and is independently selected at each occurrence from the group consisting of unsubstituted -Ci-6 alkyl, -C1-3 haloalkyl, halide, -OR 6 , and CN.
  • R 5a is one substituent attached to the para position of phenyl and is selected from the group consisting of unsubstituted -C 2- 6 alkyl, -CH2OH, -CH 2 N(R 6b ) 2 , -C2-3 haloalkyl, iodide, -OR 6a , and CN.
  • R is one substituent attached to the meta position of phenyl and is selected from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 6b ) 2 , -C2-3 haloalkyl, halide, -OR 6a , and CN.
  • R 5c is one substituent attached to the ortho position of phenyl and is selected from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, F, Br, I, -OR 6a , and CN.
  • R 5d is a substituent attached to the phenyl and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, halide, -OR 6a , and CN; z is 2 to 5.
  • R 5e is a substituent attached to the ring and is selected from the group consisting of unsubstituted -C2-5 alkyl, -CH2OH, - CH 2 N(R 6b ) 2 , -Ci-3 haloalkyl, F, I, -OR 6 , and CN; s is 1.
  • R 5f is a substituent attached to the ring and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, F, Br, I, -OR 6 , and CN; t is 1 or 2.
  • R 5f is a substituent attached to the ring and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, F, Br, I, -OR 6 , and CN; t is 0 to 2.
  • R 5g is a substituent attached to the ring and is independently selected at each occurrence from the group consisting of unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, halide, -OR 6 , and CN; u is 1 to 3.
  • R 5h is a substituent attached to the ring and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH2OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, halide, -OR 6 , and CN; v is 1 or 2.
  • R 5h is a substituent attached to the ring and is independently selected at each occurrence from the group consisting of
  • R Sl is substituent attached to the ring and is independently selected at each occurrence from the group consisting of H, H, unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, halide, -OR 6 , and CN; w is 1 to 4.
  • R Sl is substituent attached to the ring and is independently selected at each occurrence from the group consisting of H, unsubstituted -Ci_ 6 alkyl, -CH 2 OH, -CH 2 N(R 6b ) 2 , -C1-3 haloalkyl, halide, -OR 6 , and CN; w is 0 to 4.
  • each R 6 is independently selected from the group consisting of H, unsubstituted -C 1-6 alkyl, and -C1-3 haloalkyl.
  • each R 6a is independently selected from the group consisting of unsubstituted -C 2-6 alkyl and -C1-3 haloalkyl.
  • each R 6b is independently selected from the group consisting of H and unsubstituted -C1-3 alkyl.
  • each U is independently N or C.
  • At least one U must be C.
  • Q is S or O.
  • At least one U must be N and at least one U must be C.
  • p is 0 to 3.
  • p is 1 to 3.
  • Ring D is selected from the group

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2015/046120 2014-08-20 2015-08-20 Gamma-diketones for treatment and prevention of aging skin and wrinkles Ceased WO2016029021A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
JP2017529598A JP6766047B2 (ja) 2014-08-20 2015-08-20 加齢皮膚およびしわの処置用および予防用のγ−ジケトン
EP15833863.2A EP3206686B1 (en) 2014-08-20 2015-08-20 Gamma-diketones for treatment and prevention of aging skin and wrinkles
KR1020177007464A KR102165385B1 (ko) 2014-08-20 2015-08-20 피부 노화 및 주름의 치료 및 예방을 위한 감마-디케톤
MX2017002285A MX368248B (es) 2014-08-20 2015-08-20 Gamma-dicetonas para tratamiento y prevencion de piel envejecida y arrugas.
ES15833863T ES2762559T3 (es) 2014-08-20 2015-08-20 Gamma-dicetonas para tratamiento y prevención de envejecimiento de la piel y arrugas
DK15833863.2T DK3206686T3 (da) 2014-08-20 2015-08-20 Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker
SM20190709T SMT201900709T1 (it) 2014-08-20 2015-08-20 Gamma-dichetoni per trattamento e prevenzione di pelle in invecchiamento e rughe
RU2017108750A RU2727039C2 (ru) 2014-08-20 2015-08-20 Гамма-дикетоны для лечения и профилактики старения кожи и морщин
SI201530999T SI3206686T1 (sl) 2014-08-20 2015-08-20 Gama-diketoni za zdravljenje in preprečevanje staranja kože in gub
MA40454A MA40454B1 (fr) 2014-08-20 2015-08-20 Gamma-dicétones pour le traitement et la prévention des rides et du vieillissement de la peau
LTEP15833863.2T LT3206686T (lt) 2014-08-20 2015-08-20 Gama-diketonai, skirti senėjančios odos ir raukšlių gydymui ir profilaktikai
CN201580056841.7A CN107106549B (zh) 2014-08-20 2015-08-20 用于治疗和预防老化皮肤和皱纹的γ–二酮
CA2958580A CA2958580C (en) 2014-08-20 2015-08-20 Gamma-diketones for treatment and prevention of aging skin and wrinkles
AU2015305373A AU2015305373B2 (en) 2014-08-20 2015-08-20 Gamma-diketones for treatment and prevention of aging skin and wrinkles
BR112017003959-1A BR112017003959B1 (pt) 2014-08-20 2015-08-20 Uso de um composto de fórmula i ou um sal dermatologicamente aceitável do mesmo
HRP20192161TT HRP20192161T1 (hr) 2014-08-20 2015-08-20 Gama-diketoni za liječenje i prevenciju starenja kože i bora
RS20191605A RS59797B1 (sr) 2014-08-20 2015-08-20 Gama-diketoni za tretman i prevenciju starenja kože i bora
PL15833863T PL3206686T3 (pl) 2014-08-20 2015-08-20 gamma-Diketony do leczenia i zapobiegania starzeniu się skóry i zmarszczkom
IL250663A IL250663B (en) 2014-08-20 2017-02-19 Gamma-diketones for the treatment and prevention of skin aging and wrinkles
ZA2017/01460A ZA201701460B (en) 2014-08-20 2017-02-27 Gamma-diketones for treatment and prevention of aging skin and wrinkles
CY20191101314T CY1122603T1 (el) 2014-08-20 2019-12-16 Γαμμα-δικετονες για τη θεραπευτικη αντιμετωπιση και την προληψη της γηρανσης του δερματος και των ρυτιδων

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462039786P 2014-08-20 2014-08-20
US62/039,786 2014-08-20

Publications (1)

Publication Number Publication Date
WO2016029021A1 true WO2016029021A1 (en) 2016-02-25

Family

ID=55351257

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/046120 Ceased WO2016029021A1 (en) 2014-08-20 2015-08-20 Gamma-diketones for treatment and prevention of aging skin and wrinkles

Country Status (26)

Country Link
US (4) US9795550B2 (https=)
EP (1) EP3206686B1 (https=)
JP (1) JP6766047B2 (https=)
KR (1) KR102165385B1 (https=)
CN (1) CN107106549B (https=)
AU (1) AU2015305373B2 (https=)
BR (1) BR112017003959B1 (https=)
CA (1) CA2958580C (https=)
CL (1) CL2017000410A1 (https=)
CY (1) CY1122603T1 (https=)
DK (1) DK3206686T3 (https=)
ES (1) ES2762559T3 (https=)
HR (1) HRP20192161T1 (https=)
HU (1) HUE046741T2 (https=)
IL (1) IL250663B (https=)
LT (1) LT3206686T (https=)
MA (1) MA40454B1 (https=)
MX (1) MX368248B (https=)
PL (1) PL3206686T3 (https=)
PT (1) PT3206686T (https=)
RS (1) RS59797B1 (https=)
RU (1) RU2727039C2 (https=)
SI (1) SI3206686T1 (https=)
SM (1) SMT201900709T1 (https=)
WO (1) WO2016029021A1 (https=)
ZA (1) ZA201701460B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069406A (zh) * 2016-04-14 2018-12-21 宝洁公司 改善眶周性色素异常的外观的方法
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
US11162071B2 (en) 2018-08-17 2021-11-02 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating JAG-1
US11433006B2 (en) 2019-02-25 2022-09-06 Topix Pharmaceuticals, Inc. Methods, compositions, and delivery systems for therapeutic skin treatments
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
AU2023209421B2 (en) * 2022-01-18 2026-04-09 IC-MedTech Corp. Bicyclic quinones, pharmaceutical compositions, and therapeutic applications

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2592694C2 (ru) 2010-08-18 2016-07-27 СЭМЬЮМЕД, ЭлЭлСи Дикетоны и гидроксикетоны в качестве активатора сигнального пути катенина
DK2968249T3 (en) 2013-02-22 2019-03-04 Samumed Llc GAMMA DIKETONS AS WNT / BETA-CATENIN SIGNAL ROAD ACTIVATORS
MA40454B1 (fr) 2014-08-20 2020-01-31 Samumed Llc Gamma-dicétones pour le traitement et la prévention des rides et du vieillissement de la peau
PL3313369T3 (pl) * 2015-08-04 2021-04-06 Eupharma Pty Ltd Kompozycja emolientu
EP3393604B1 (en) * 2015-12-24 2026-02-11 Unilever Global IP Limited Tyrosinase inhibitors
US10463601B1 (en) * 2016-06-17 2019-11-05 Lorita Dillon Topical cosmetic composition
WO2018081005A1 (en) * 2016-10-25 2018-05-03 Access Business Group International Llc Compositions of lithospermum erythrorhizon (gromwell root) and methods of making and using the compositions
EP3638276A4 (en) * 2017-06-13 2020-11-25 Mary Kay Inc. COSMETIC COMPOSITIONS AND METHODS FOR USE IN SKIN FIRMING
US11318179B2 (en) 2017-06-20 2022-05-03 Jessica Kado Topical formulation for binding to dermatological cannabinoid receptors
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
EP3793508A1 (en) * 2018-05-14 2021-03-24 Johnson & Johnson Consumer Inc. Moisturizing cream and lotion
CN108813246A (zh) * 2018-05-31 2018-11-16 陕西顾森健康科技有限公司 一种易吸收防流失的胶原蛋白肽抗衰组合物及其制备工艺
US10980851B2 (en) * 2018-06-08 2021-04-20 The Procter & Gamble Company Topical skincare compositions comprising Centella asiatica selected triterpenes
KR101938877B1 (ko) * 2018-08-20 2019-01-16 안디바 주식회사 수딩크림 조성물 및 그의 제조방법
CN109394570A (zh) * 2018-11-08 2019-03-01 杭州百芮生物科技有限公司 一种超分子水杨酸复合凝胶及其制备方法
KR102021014B1 (ko) * 2018-11-21 2019-09-16 신민지 가슴 크림 제조방법 및 이에 의해 제조된 가슴 크림
DE102018131724A1 (de) * 2018-12-11 2020-06-18 Wellstar Gmbh & Co. Kg Zusammensetzung und Verwendung der Zusammensetzung als Anti-Aging-Mittel
KR101987099B1 (ko) * 2018-12-19 2019-06-10 주식회사 메디셀 피부온도 감응형 기능성 하이드로겔 조성물을 이용한 팔뚝 붓기완화용 패치 및 그 제조방법
KR102031885B1 (ko) * 2019-01-08 2019-10-15 안디바 주식회사 마카 추출물을 함유한 수딩크림 조성물
CN109820802A (zh) * 2019-04-11 2019-05-31 冯江 一种亮颜润肤精华液及其制备方法
CN109925248B (zh) * 2019-04-28 2021-10-19 青岛科技大学 一种含有根皮素、三七总皂苷抗皮肤光老化作用的护肤组合物
FR3097558B1 (fr) * 2019-06-24 2021-06-25 Oreal Méthode de diagnostic d’un vieillissement prématuré de la peau
US11633368B2 (en) 2019-09-03 2023-04-25 Milton D. Moore Enhanced moisturizing lotion compositions
CN110711161A (zh) * 2019-11-03 2020-01-21 广州悦荟化妆品有限公司 一种免洗型的舒敏修护精华面膜
KR102369744B1 (ko) * 2019-12-24 2022-03-03 경희대학교 산학협력단 부들레야 다비디 추출물을 포함하는 항염증용 조성물
US20210251852A1 (en) * 2020-02-14 2021-08-19 Tiwona Ross Aloe Mint Scalp Wipes
WO2021168474A1 (en) * 2020-02-17 2021-08-26 Mary Kay Inc. Topical cosmetic compositions
EP4120848A4 (en) * 2020-03-17 2024-07-24 Epidarus Therapeutics, LLC COMPOSITIONS FOR INHIBITING THE DEGRADATION OF HYALURONIC ACID AND METHODS OF USE THEREOF
CN111297736A (zh) * 2020-03-18 2020-06-19 苏州工业园区黛宜菲化妆品有限公司 一种具有修护皮脂膜作用的修颜油
CN111388376B (zh) * 2020-04-20 2022-06-21 广西诗琳茉莉生物科技集团有限公司 一种茉莉草本抗敏舒缓面膜及其制备方法
US11213473B1 (en) * 2020-09-18 2022-01-04 Christopher Zoumalan Skin brightening composition
KR102233707B1 (ko) * 2021-01-06 2021-03-29 김현숙 천연 추출물 및 천연 가루를 포함하는 화장료 조성물
AU2022214447A1 (en) * 2021-01-29 2023-08-10 ChromaDex Inc. Ethyl cellulose based coatings for microencapsulation of nicotinamide riboside and other nicotinyl riboside compounds
CN112870108A (zh) * 2021-02-07 2021-06-01 上海百雀羚生物科技有限公司 一种具有抗衰老、保湿功效的组合物及其制备方法和应用
US11642305B2 (en) 2021-06-03 2023-05-09 Melissa Kadzai Composition for a skin and hair product
CN113876641A (zh) * 2021-11-05 2022-01-04 上海新高姿化妆品有限公司 一种具有抗皱紧致功效的化妆品组合物及其应用
US11484489B1 (en) * 2021-12-08 2022-11-01 Codex Beauty Corporation Skin care compositions and methods for regulating sebum production
CN113956244B (zh) * 2021-12-21 2022-03-29 浙江湃肽生物有限公司深圳分公司 一种用于皮肤复新的肌肽衍生物及其用途
KR20240146665A (ko) 2022-01-07 2024-10-08 오디티 랩스, 엘엘씨 피부 치료를 위한 조성물, 제제 및 방법
CN114432207B (zh) * 2022-03-09 2023-06-16 上海柒色生物科技有限公司 一种长效保湿修复组合物、修复霜及其制备方法
US12194120B2 (en) 2022-05-31 2025-01-14 Heidi Skin, Llc Skin care formulation containing silver nanoparticles
CN115804736B (zh) * 2022-12-14 2024-04-26 广州臻颜化妆品有限公司 一种多效润唇膏及其制备方法
CN116712359B (zh) * 2023-03-27 2025-02-11 山东福瑞达生物股份有限公司 一种益生菌发酵复合植物提取物的制备及应用
CN116807932A (zh) * 2023-08-10 2023-09-29 羽楠(广州)化妆品有限公司 一种海洋来源的抗皱紧致组合物及其应用以及包括该组合物的精华液及其制备方法
KR102597707B1 (ko) * 2023-09-07 2023-11-03 (주)스타팜텍 얼굴 주름 개선 및 미백 효과를 가지는 기능성 화장품 조성물
KR102869831B1 (ko) * 2023-09-19 2025-10-14 주식회사 코리아나화장품 풀루란, 피브이엠/엠에이코폴리머 및 바다포도추출물을 포함하는 피부 리프팅용 화장료 조성물
CN117598924B (zh) * 2023-11-30 2024-06-18 广州市仙迪生物科技有限公司 一种植物多肽组合物及其应用
CN117653563B (zh) * 2023-12-13 2024-06-04 奥俐莱雅（广东）家化科技有限公司 一种高透皮性的重组胶原蛋白肽及其制备工艺和应用
CN117797081B (zh) * 2024-01-02 2025-10-17 诺斯贝尔化妆品股份有限公司 一种控油舒缓祛痘组合物及其制备方法和应用
CN119039469B (zh) * 2024-08-01 2026-04-03 华南理工大学 一种酶法提取的刺梨多糖及其制备方法与应用
PL452068A1 (pl) * 2025-05-16 2026-03-16 Vgs Polska Spółka Z Ograniczoną Odpowiedzialnością Naturalny krem do twarzy nawilżający

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420273A (en) * 1988-07-14 1995-05-30 Hoffman-La Roche Inc. Condensed heterocyclic compounds
WO2001049291A1 (en) * 1999-12-29 2001-07-12 Research Triangle Institute 10,11-difluoromethylenedioxycamptothecin compounds with topoisomerase i inhibition
US20030087922A1 (en) * 2001-03-29 2003-05-08 Bethiel Randy S. Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
US20070185152A1 (en) * 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
WO2007103584A2 (en) * 2006-03-09 2007-09-13 Nanovir, Llc Polyamides for treating human papilloma virus
US20100210036A1 (en) * 2003-07-17 2010-08-19 Plexxikon, Inc. Ppar active compounds
WO2011009826A2 (en) * 2009-07-21 2011-01-27 ADAMED Sp.z o.o. Novel chalcone derivatives with cytotoxic activity
US20130172291A1 (en) * 2011-09-07 2013-07-04 Island Kinetics Inc. Retinal cyclodextrin acetals and hemiacetals for treating skin complexion disorder
WO2013113722A1 (en) * 2012-01-30 2013-08-08 Universiteit Gent Anti-invasive compounds
US20140005228A1 (en) * 2010-08-18 2014-01-02 Samumed, Llc B- and y -diketones and y -hydroxyketones as wnt/ b -catenin signaling pathway activators
US20140179642A1 (en) * 2012-12-20 2014-06-26 Avon Products, Inc. Collagen Stimulators and Their Use in the Treatment of Skin

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3040054A (en) 1960-08-03 1962-06-19 Olin Mathieson 2, 2'-(1, 4-diaminotetramethylene) bis(4-thiazolecarboxylic acid), salts and process
US3855675A (en) 1971-05-25 1974-12-24 Squibb & Sons Inc 1-(2-furanylmethyl)-1h-pyrazolo(3,4-b)pyridine-5-methanones
US4014889A (en) 1972-12-20 1977-03-29 Bayer Aktiengesellschaft Process for preparing ketones
US4032526A (en) 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
DE2808070A1 (de) 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US4761471A (en) 1980-08-04 1988-08-02 The Regents Of The University Of California Bone morphogenetic protein composition
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
DE3331692A1 (de) 1983-09-02 1985-03-28 Basf Ag, 6700 Ludwigshafen 3-phenyl-4-methoxycarbonylpyrazole, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
EP0230110A1 (en) 1985-11-30 1987-07-29 FISONS plc Pharmacologically active pyrrole and pyrazole derivatives
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
EP0290442A4 (en) 1986-11-19 1990-07-03 Chemex Pharmaceuticals Inc MEDICINAL PREPARATIONS AND MIXTURES THEREOF, ORGANIC COMPOSITIONS AND METAL SALTS.
FR2613360B1 (fr) * 1987-04-03 1989-06-09 Oreal Nouveaux derives aromatiques d'acide butyrique, leur procede de preparation et leur utilisation en medecine humaine et veterinaire ainsi qu'en cosmetique
NZ227287A (en) 1987-12-21 1992-01-29 Merck & Co Inc 2,5-diaryl tetrahydrofurans and medicaments
IL91418A (en) 1988-09-01 1997-11-20 Rhone Poulenc Agrochimie (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them
EP0365089A3 (en) 1988-10-18 1991-06-05 Merck & Co. Inc. 2-aryl-5(3-methoxy-5-(hydroxypropylsulfonyl)-4-propoxyphenyl) tetrahydrothiophen and analogs
DK0429570T3 (da) 1989-03-28 1998-04-27 Genetics Inst Osteoinducerende præparater
ATE124394T1 (de) 1990-04-27 1995-07-15 Duphar Int Res Verfahren zur photochemischen isomerisierung von organischen verbindungen unter dem einfluss eines photosensibilisators.
DE4104931A1 (de) 1991-02-18 1992-08-20 Hoechst Ag Verfahren zur herstellung substituierter indene
JPH05170764A (ja) 1991-12-24 1993-07-09 Sumitomo Pharmaceut Co Ltd 新規なヒドロキシカルコン誘導体
GB9203806D0 (en) 1992-02-21 1992-04-08 Unilever Plc Sunscreen agents
DK57892D0 (da) 1992-05-01 1992-05-01 Nkt Res Center As Fremgangsmaade til fremstilling af 1,4-bis-aryl-butan-1,4-dioner og poly(arylen-butan-1,4-dioner)
US5760053A (en) 1994-10-07 1998-06-02 Meiji Seika Kabushiki Kaisha γ-Diketone compounds with inhibitory activity against platelet aggregation
WO1996021665A1 (en) 1995-01-13 1996-07-18 Board Of Regents, The University Of Texas System Turcasarins, novel expanded porphyrins, and uses thereof
US5668148A (en) 1995-04-20 1997-09-16 Merck & Co., Inc. Alpha1a adrenergic receptor antagonists
US5585118A (en) 1995-06-02 1996-12-17 Brigham And Women's Hospital Choline in the treatment of bipolar disorder
US5668165A (en) 1995-06-07 1997-09-16 Scriptgen Pharmaceuticals, Inc. Small molecule inhibition of RNA/ligand binding
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
CN1216522A (zh) 1996-02-19 1999-05-12 日本烟草产业株式会社 糖尿病治疗剂
DE69724472T2 (de) 1996-06-03 2004-06-17 Purdue Research Foundation, West Lafayette Selenophen-antitumormittel
US6620804B2 (en) 1996-06-03 2003-09-16 Purdue Research Foundation Selenophene anti-tumor agents
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
BR9912907A (pt) 1998-08-11 2001-05-08 Bayer Agrochem Kk Pirazóis nematicidas
CA2348267A1 (en) 1998-10-29 2000-05-11 Henry H. Gu Novel inhibitors of impdh enzyme
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
AU5880600A (en) 1999-06-25 2001-01-31 Merck & Co., Inc. 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
EP1067195B1 (de) 1999-07-09 2006-09-20 Forschungszentrum Jülich Gmbh Verfahren zur Reduktion von Ketogruppen enthaltende Verbindungen
US6579984B1 (en) 1999-07-13 2003-06-17 Lonza Ag Process for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate
DE60019505T2 (de) 1999-08-06 2005-09-15 Ciba Speciality Chemicals Holding Inc. Mikrobizide Wirksubstanzen
AUPQ288499A0 (en) 1999-09-16 1999-10-07 Biota Scientific Management Pty Ltd Antiviral agents
DE60025744D1 (de) 1999-10-07 2006-04-13 Lilly Co Eli Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
JP2001294581A (ja) 2000-04-12 2001-10-23 Nippon Bayer Agrochem Co Ltd イソチアゾール誘導体
US6794362B1 (en) 2000-05-30 2004-09-21 Connective Tissue Imagineering Llc Asparagine containing elastin peptide analogs
US6960591B2 (en) 2000-07-05 2005-11-01 Yamanouchi Pharmaceutical Co., Ltd. Propane-1,3-dione derivative
US20020022040A1 (en) 2000-07-10 2002-02-21 The Proctor & Gamble Company Methods of enhancing delivery of oil-soluble skin care actives
DE10059749A1 (de) 2000-12-01 2002-06-20 Henkel Kgaa Fixierung von Wirkstoffen an fasrigen Materialien
CA2439415C (en) 2001-03-02 2011-09-20 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
CN1259316C (zh) * 2001-04-05 2006-06-14 托伦脱药品有限公司 用于老龄相关性和糖尿病性血管系统并发症的杂环类化合物
CA2444882A1 (en) 2001-04-30 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of gsk-3 and crystal structures of gsk-3.beta. protein and protein complexes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
WO2003016266A1 (fr) 2001-08-16 2003-02-27 Japan Tobacco Inc. Composes $g(b)-cetoamides et leur utilisation medicinale
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
EP1440688A4 (en) 2001-10-11 2005-11-30 Kaneka Corp PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR LIGANDS AND METHOD OF MANUFACTURING THE SAME
CN1155590C (zh) 2002-04-12 2004-06-30 中国药科大学 具有抗肿瘤活性的色酮类化合物及其开环产物与制备方法
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US20040266732A1 (en) 2002-09-20 2004-12-30 Jorge Galvez Therapeutic agents, methods, and treatments
FR2849598B1 (fr) 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
US20040224003A1 (en) 2003-02-07 2004-11-11 Schultz Robert K. Drug formulations for coating medical devices
DE602004012083T2 (de) 2003-04-15 2009-04-23 Astrazeneca Ab Neue Verbindungen, die als Verstärker von Glutamatrezeptoren dienen
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US20050175562A1 (en) 2004-01-05 2005-08-11 Anke Hadasch Skin makeup composition
US20060276536A1 (en) 2004-02-12 2006-12-07 Vander Jagt David L Cancer treatment using curcumin derivatives
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
RU2006142896A (ru) 2004-05-06 2008-06-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния (Us) Замещенные енаминоны, их производные и их применение
US7709519B2 (en) 2004-06-04 2010-05-04 Astellas Pharma Inc. Benzimidazolylidene propane-1,3 dione derivative or salt thereof
DE102004029309A1 (de) 2004-06-17 2005-12-29 Bayer Cropscience Gmbh Pyridinylisoxazole und ihre Verwendung als Herbizide
EP2298291A3 (en) 2004-06-18 2011-08-03 Agennix USA Inc. Kinase inhibitors for treating cancers
CA2577169A1 (en) 2004-08-16 2006-02-23 The University Of Queensland Metabolism-modulating agents and uses therefor
US7351745B2 (en) * 2004-12-22 2008-04-01 Avon Products, Inc Compositions and methods of their use for improving the condition and appearance of skin
FR2880802B1 (fr) 2005-01-14 2008-12-19 Sederma Soc Par Actions Simpli Composition cosmetique ou dermopharmaceutique contenant un extrait d'euglene
JP2008094720A (ja) 2005-01-20 2008-04-24 Astellas Pharma Inc キノロン誘導体のプロドラッグ又はその塩
US20060264897A1 (en) 2005-01-24 2006-11-23 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
CN101111489A (zh) 2005-02-01 2008-01-23 惠氏公司 作为β-分泌酶的抑制剂的氨基-吡啶
EP1864976B1 (en) 2005-03-31 2012-10-10 Astellas Pharma Inc. Propane-1,3-dion derivative or salt thereof
US8178727B2 (en) 2005-06-27 2012-05-15 National University Corporation Tohoku University Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer
DE102005031580A1 (de) 2005-07-06 2007-01-11 Aicuris Gmbh & Co. Kg Substituierte Sulfolanylpyrazole und ihre Verwendung
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007051314A1 (en) 2005-11-07 2007-05-10 American Diagnostica Inc. Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1
DK1954274T3 (da) 2005-11-10 2011-01-31 Chemocentryx Inc Substituerede quinoloner og fremgangsmåder til anvendelse
EP2004596A2 (en) 2006-04-11 2008-12-24 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
JP2008007428A (ja) 2006-06-27 2008-01-17 Showa Denko Kk 皮膚外用シワ防止剤
WO2008020625A1 (en) 2006-08-17 2008-02-21 Kanazawa University Dibenzoylmethane compound and pharmaceutical composition comprising the compound as active ingredient
CN101505721B (zh) 2006-08-30 2013-12-18 株式会社益力多本社 皱纹形成抑制剂
US7875603B2 (en) 2006-09-21 2011-01-25 Nova Southeastern University Specific inhibitors for vascular endothelial growth factor receptors
JP5207341B2 (ja) 2006-10-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
JP5231829B2 (ja) 2007-02-15 2013-07-10 石原産業株式会社 ピリジル−トリアゾロピリミジン誘導体又はその塩、それらを含有する有害生物防除剤並びにそれらの製造方法
WO2008118626A2 (en) 2007-03-08 2008-10-02 Burnham Institute For Medical Research Inhibitors of jnk and methods for identifying inhibitors of jnk
JP5309318B2 (ja) 2007-03-09 2013-10-09 国立大学法人 岡山大学 エステル、カルボン酸及びアミドの製造方法
JP2010524911A (ja) 2007-04-18 2010-07-22 アストラゼネカ アクチボラグ ５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用
KR101404398B1 (ko) 2007-06-20 2014-06-09 (주)뉴트리 주름개선 화장료 조성물
BRPI0820327A2 (pt) 2007-11-02 2020-10-06 Novartis Ag moléculas e métodos para modulação de proteína relacionada ao receptor de lipoproteína de baixa densidade 6 (lrp6)
US20100267626A1 (en) 2007-11-05 2010-10-21 Novartis Ag Methods and compositions for measuring wnt activation and for treating wnt-related cancers
WO2009071997A2 (en) 2007-12-06 2009-06-11 Centre National De La Recherche Scientifique (C.N.R.S.) Iron and copper catalytic systems for cross-coupling reactions
JP2009179619A (ja) 2008-02-01 2009-08-13 Toyo Ink Mfg Co Ltd 新規オキシムエステル化合物およびそれを含んでなるラジカル重合開始剤および重合性組成物
AU2009219359A1 (en) 2008-02-27 2009-09-03 Msd Consumer Care, Inc. Enhanced photostability of suncare compositions containing avobenzone
WO2009129267A2 (en) 2008-04-14 2009-10-22 The Board Of Regents Of The University Of Texas System Small molecule inhibitors of the pleckstrin homology domain and methods for using same
JP5436544B2 (ja) 2008-05-08 2014-03-05 ノヴァ サウスイースタン ユニバーシティ− 血管内皮増殖因子受容体に特異的な阻害剤
KR101535319B1 (ko) 2008-11-05 2015-07-10 유니버시티 오브 써던 캘리포니아 후생적 조절의 소형 분자 조절물질, 그리고 이들의 치료적 적용
US20130039998A1 (en) 2008-12-24 2013-02-14 University Of Washington Compositions of modulators of the wnt/beta-catenin pathway and benzamide and/or hydroxamic acid derivatives to treat bipolar disorder
JP5246715B2 (ja) 2009-01-27 2013-07-24 独立行政法人科学技術振興機構 蛋白質架橋阻害剤およびその用途
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
KR101784940B1 (ko) 2010-08-31 2017-10-12 (주)아모레퍼시픽 피부 탄력 개선용 화장료 조성물
AU2012212323A1 (en) 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
KR101285259B1 (ko) * 2011-08-04 2013-07-11 (주)케어젠 Ｗｎｔ 계열 유래 펩타이드 및 이의 용도
US9668691B2 (en) 2011-09-22 2017-06-06 Lvmh Recherche Method to measure skin elasticity and firmness
US20130302381A1 (en) 2012-05-09 2013-11-14 Cook Medical Technologies Llc Implantable Medical Devices Including a Water-Insoluble Therapeutic Agent
RU2652265C2 (ru) 2013-02-22 2018-04-27 Х. Лундбекк А/С Способ получения вортиоксетина
ES2731681T3 (es) 2013-02-22 2019-11-18 Abbvie Stemcentrx Llc Conjugados de anticuerpo anti-DLL3 y PBD y usos de los mismos
GEP201606600B (en) 2013-02-22 2017-01-10 Pfizer Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
DK2968249T3 (en) 2013-02-22 2019-03-04 Samumed Llc GAMMA DIKETONS AS WNT / BETA-CATENIN SIGNAL ROAD ACTIVATORS
MA40454B1 (fr) 2014-08-20 2020-01-31 Samumed Llc Gamma-dicétones pour le traitement et la prévention des rides et du vieillissement de la peau

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420273A (en) * 1988-07-14 1995-05-30 Hoffman-La Roche Inc. Condensed heterocyclic compounds
WO2001049291A1 (en) * 1999-12-29 2001-07-12 Research Triangle Institute 10,11-difluoromethylenedioxycamptothecin compounds with topoisomerase i inhibition
US20030087922A1 (en) * 2001-03-29 2003-05-08 Bethiel Randy S. Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
US20100210036A1 (en) * 2003-07-17 2010-08-19 Plexxikon, Inc. Ppar active compounds
US20070185152A1 (en) * 2004-03-02 2007-08-09 Smithkline Beecham Corporation Inhibitors of akt activity
WO2007103584A2 (en) * 2006-03-09 2007-09-13 Nanovir, Llc Polyamides for treating human papilloma virus
WO2011009826A2 (en) * 2009-07-21 2011-01-27 ADAMED Sp.z o.o. Novel chalcone derivatives with cytotoxic activity
US20140005228A1 (en) * 2010-08-18 2014-01-02 Samumed, Llc B- and y -diketones and y -hydroxyketones as wnt/ b -catenin signaling pathway activators
US20130172291A1 (en) * 2011-09-07 2013-07-04 Island Kinetics Inc. Retinal cyclodextrin acetals and hemiacetals for treating skin complexion disorder
WO2013113722A1 (en) * 2012-01-30 2013-08-08 Universiteit Gent Anti-invasive compounds
US20140179642A1 (en) * 2012-12-20 2014-06-26 Avon Products, Inc. Collagen Stimulators and Their Use in the Treatment of Skin

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069406A (zh) * 2016-04-14 2018-12-21 宝洁公司 改善眶周性色素异常的外观的方法
US11066419B2 (en) 2016-12-30 2021-07-20 Frequency Therapeutics, Inc. 1H-pyrrole-2,5-dione compounds and methods of using same
US11162071B2 (en) 2018-08-17 2021-11-02 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating JAG-1
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
US11433006B2 (en) 2019-02-25 2022-09-06 Topix Pharmaceuticals, Inc. Methods, compositions, and delivery systems for therapeutic skin treatments
US12064494B2 (en) 2019-02-25 2024-08-20 Topix Pharmaceuticals, Inc. Methods, compositions, and delivery systems for therapeutic skin treatments
AU2023209421B2 (en) * 2022-01-18 2026-04-09 IC-MedTech Corp. Bicyclic quinones, pharmaceutical compositions, and therapeutic applications

Also Published As

Publication number Publication date
RU2017108750A (ru) 2018-09-23
PT3206686T (pt) 2020-01-06
CY1122603T1 (el) 2021-03-12
US20180193244A1 (en) 2018-07-12
PL3206686T3 (pl) 2020-04-30
RU2017108750A3 (https=) 2019-04-02
US20220087917A1 (en) 2022-03-24
MX368248B (es) 2019-09-25
MA40454B1 (fr) 2020-01-31
JP2017525767A (ja) 2017-09-07
ES2762559T3 (es) 2020-05-25
RS59797B1 (sr) 2020-02-28
ZA201701460B (en) 2023-12-20
US11077046B2 (en) 2021-08-03
KR102165385B1 (ko) 2020-10-15
US10434052B2 (en) 2019-10-08
RU2727039C2 (ru) 2020-07-17
BR112017003959A2 (pt) 2018-12-18
CA2958580A1 (en) 2016-02-25
IL250663B (en) 2020-09-30
US20160206540A1 (en) 2016-07-21
IL250663A0 (en) 2017-04-30
EP3206686A4 (en) 2018-04-11
MX2017002285A (es) 2018-01-23
KR20170066342A (ko) 2017-06-14
CN107106549A (zh) 2017-08-29
CA2958580C (en) 2023-10-24
US20200222295A1 (en) 2020-07-16
CL2017000410A1 (es) 2017-10-30
EP3206686B1 (en) 2019-10-09
AU2015305373B2 (en) 2020-12-10
US9795550B2 (en) 2017-10-24
DK3206686T3 (da) 2019-12-16
HUE046741T2 (hu) 2020-03-30
JP6766047B2 (ja) 2020-10-07
EP3206686A1 (en) 2017-08-23
US11839679B2 (en) 2023-12-12
LT3206686T (lt) 2020-01-10
CN107106549B (zh) 2020-06-16
HRP20192161T1 (hr) 2020-02-21
SMT201900709T1 (it) 2020-01-14
SI3206686T1 (sl) 2020-03-31
AU2015305373A1 (en) 2017-03-16
BR112017003959B1 (pt) 2022-08-02

Similar Documents

Publication Publication Date Title
US11839679B2 (en) Gamma-diketones for treatment and prevention of aging skin and wrinkles
KR101772139B1 (ko) 피부 케어 제형
KR102245069B1 (ko) 피부톤 향상을 위한 식물 추출물의 조합물
CN113633571A (zh) 亮白增强技术和亮白安瓿
CN113616539A (zh) 化妆品组合物
US8790710B1 (en) Topical composition comprising umbilical cord blood serum
HK1240093B (en) Gamma-diketones for treatment and prevention of aging skin and wrinkles
HK1240093A1 (en) Gamma-diketones for treatment and prevention of aging skin and wrinkles
US20250049679A1 (en) Formulations of eriodictyol
AU2024269821A1 (en) Formulations of pectolinarigenin
AU2024326054A1 (en) Formulations of dihydrokaempferol
KR20260009864A (ko) 나린게닌의 제제
HK1192156B (en) Topical skin care formulations comprising jaboticaba and cashew fruit pulps and extracts thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15833863

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2958580

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 250663

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2017529598

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/002285

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017003959

Country of ref document: BR

REEP Request for entry into the european phase

Ref document number: 2015833863

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015833863

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2017/0188.1

Country of ref document: KZ

ENP Entry into the national phase

Ref document number: 2015305373

Country of ref document: AU

Date of ref document: 20150820

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20177007464

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2017108750

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112017003959

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170224

REG Reference to national code

Ref country code: BR

Ref legal event code: B01D

Ref document number: 112017003959

Country of ref document: BR

Kind code of ref document: A2

Free format text: O PRESENTE PEDIDO FOI DEPOSITADO ATRAVES DO PCT/US2015/046120 DE 20/08/2015 , DANDOENTRADA NA FASE NACIONAL EM 24/02/2017 , APESAR DO PRAZO EXPIRAR EM 20/02/2017 (30 MESESCONTADOS DA DATA DE PRIORIDADE).JUNTAMENTE COM A PETICAO DE ENTRADA, O DEPOSITANTE SOLICITOU RESTABELECIMENTO PARA A ENTRADANO BRASIL COM BASE NA REGRA 49.6 DO PCT, JUSTIFICANDO QUE NESSE MESMO DIA,O SISTEMADE PETICIONAMENTO DO INPI APRESENTOU FALHAS, DE MODO QUE A REQUERENTEFOI IMPOSSIBILITADA DE CUMPRIR TAL PRAZOA ALEGACAO BASEIA-SE NO FATO DE A REQUERENTE, NA SEGUNDA-FEIRA, DIA 20/02/2017,E POR SUCESSIVAS VEZES, TENTOU ENVIAR ELETRONICAMENTE AO INPI A PETICAODE ENTRADA NACIONAL DO REFERIDO PCT. TODAS AS TENTATIVAS FORAMF

ENP Entry into the national phase

Ref document number: 112017003959

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170224